ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.

Marcia S Brose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.